NEXM

NexMed Inc. is very active in pre market trading today due to the company licensing it's experimental nail fungus treatment to drug maker Novartis AG. The deal worth $4 million could lead to potential payments up to $47 million. Keep this stock on that trading radar.

Budd Foxx